▲ bullish
Impact
PhasePhase 3
Time to marketIf LEVEL Phase 3 data is positive (Aug 2026), Tenax would need to complete a second registrational study (LEVEL-2) and file an NDA. Realistic best-case US approval would be 2028-2029, assuming positive results and a standard FDA review cycle.
levosimendan Updated Jul 2
What to watch
The Phase 3 LEVEL topline readout in August 2026 is a make-or-break binary catalyst. Positive data could unlock a ~$2B+ market opportunity as the first approved therapy for PH-HFpEF, while a miss would likely devastate the stock. With a strong cash runway (~$118.8M through Q1 2028), no near-term dilution risk exists. This is a pure binary options-style biotech setup, size accordingly.
Bull case
- PH-HFpEF is a large, underserved market with zero FDA-approved therapies, oral levosimendan could be first-to-market if LEVEL succeeds.
- Phase 2 data showed IV levosimendan produced statistically significant improvements in exercise hemodynamics and 6-minute walk distance in PH-HFpEF patients, de-risking the mechanism.
- IV levosimendan is already approved in 60+ countries for related indications, providing a strong safety database and known tolerability profile.
Bear case
- The LEVEL Phase 3 readout is a binary event, failure would likely destroy the stock, as Tenax is effectively a single-asset company.
- The $100M private placement at $3/share in Aug 2024 was massively dilutive (priced at a fraction of current levels), and warrant overhang could pressure the stock.
- Competition from SGLT2 inhibitors (Farxiga, Jardiance) is expanding across HFpEF indications, potentially narrowing levosimendan's differentiation.